% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Salvato:289470,
      author       = {I. Salvato and A. Marchini$^*$},
      title        = {{I}mmunotherapeutic {S}trategies for the {T}reatment of
                      {G}lioblastoma: {C}urrent {C}hallenges and {F}uture
                      {P}erspectives.},
      journal      = {Cancers},
      volume       = {16},
      number       = {7},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2024-00792},
      pages        = {1276},
      year         = {2024},
      note         = {#LA:D490#},
      abstract     = {Despite decades of research and the best up-to-date
                      treatments, grade 4 Glioblastoma (GBM) remains uniformly
                      fatal with a patient median overall survival of less than 2
                      years. Recent advances in immunotherapy have reignited
                      interest in utilizing immunological approaches to fight
                      cancer. However, current immunotherapies have so far not met
                      the anticipated expectations, achieving modest results in
                      their journey from bench to bedside for the treatment of
                      GBM. Understanding the intrinsic features of GBM is of
                      crucial importance for the development of effective
                      antitumoral strategies to improve patient life expectancy
                      and conditions. In this review, we provide a comprehensive
                      overview of the distinctive characteristics of GBM that
                      significantly influence current conventional therapies and
                      immune-based approaches. Moreover, we present an overview of
                      the immunotherapeutic strategies currently undergoing
                      clinical evaluation for GBM treatment, with a specific
                      emphasis on those advancing to phase 3 clinical studies.
                      These encompass immune checkpoint inhibitors, adoptive T
                      cell therapies, vaccination strategies (i.e., RNA-, DNA-,
                      and peptide-based vaccines), and virus-based approaches.
                      Finally, we explore novel innovative strategies and future
                      prospects in the field of immunotherapy for GBM.},
      subtyp        = {Review Article},
      keywords     = {CAR-T cell therapy (Other) / DNA/RNA vaccines (Other) / GBM
                      (Other) / GBM immunosuppressive tumor microenvironment
                      (Other) / adoptive cell therapy (Other) / immune checkpoint
                      therapy (Other) / immunotherapy (Other) / oncolytic
                      virotherapy (Other) / vaccination therapy (Other)},
      cin          = {F230 / D490},
      ddc          = {610},
      cid          = {I:(DE-He78)F230-20160331 / I:(DE-He78)D490-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38610954},
      pmc          = {pmc:PMC11010873},
      doi          = {10.3390/cancers16071276},
      url          = {https://inrepo02.dkfz.de/record/289470},
}